The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: Variables affecting response rates and survival
Open accessAbstract
BACKGROUND: The objective of this study was to determine the prognostic variables that influence response and survival in patients with metastatic neuroendocrine tumors who are treated with hepatic arterial embolization (HAE) or chemoembolization (HACE). METHODS: Patients with metastatic neuroendocrine tumors who underwent HAE or HACE were included in this retrospective study. Follow‐up imaging studies were compared with baseline imaging to determine the radiologic response. Progression‐free survival (PFS) and overall survival (OS) were calculated using the Kaplan–Meier method. Univariate and multivariate analyses were performed to assess the prognostic variables that affected response and survival. RESULTS: The study included 69 patients with carcinoid tumors and 54 patients with pancreatic islet cell carcinomas. Patients who had carcinoid tumors had a higher response rate (66.7% vs. 35.2%; P = 0.0001) and had longer PFS (22.7 mos vs. 16.1 mos; P = 0.046) and OS (33.8 mos vs. 23.2 mos; P = 0.012) compared with patients who had islet cell carcinomas. For patients with carcinoid tumors, multivariate analysis identified male gender as the only independent risk factor for poor survival (P = 0.05). Octreotide was predictive marginally for PFS (P = 0.06). Patients who were treated with HAE had a higher response rate than patients who were treated with HACE (P = 0.004). For patients with islet cell carcinoma, an intact primary tumor, ≥ 75% liver involvement, and extrahepatic metastases were associated with reduced OS in the univariate analysis; the presence of bone metastases was the only risk factor (P = 0.031) in the multivariate analysis. Patients who were treated with HACE had a prolonged OS (31.5 mos vs. 18.2 mos) and improved response (50% vs. 25%) compared with patients who were treated with HAE, although the differences did not reach statistical significance. CONCLUSIONS: Patients with carcinoid tumors had better outcomes than patients with islet cell carcinomas. The addition of intraarterial chemotherapy to HAE did not improve the outcome of patients with carcinoid tumors, but it seemed to benefit patients with islet cell carcinomas. In patients who had carcinoid tumors, male gender predicted a poor outcome, and a trend toward prolonged PFS was observed in patients who received concomitant octreotide. An intact primary tumor, extensive liver disease, and bone metastases were associated with reduced survival in patients with islet cell carcinomas. Cancer 2005. © 2005 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepatic neuroendocrine metastases: does intervention alter outcomes?1
Chamberlain, R. S., Canes, D., Brown, K. T., Saltz, L., Jarnagin, W., Fong, Y., & Blumgart, L. H. (2000) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(00)00222-2 · Cited by 622
Arnold, R., Trautmann, M. E., Creutzfeldt, W., Benning, R., Benning, M., Neuhaus, C., Jürgensen, R., Stein, K., Schäfer, H., Bruns, C., et al. (1996) · Gut · doi:10.1136/gut.38.3.430 · Cited by 342
Yu, F., Venzon, D. J., Serrano, J., Goebel, S. U., Doppman, J. L., Gibril, F., & Jensen, R. T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.615 · Cited by 341
The Management of Patients with Advanced Carcinoid Tumors and Islet Cell Carcinomas
Moertel, C. G., Johnson, C. M., McKusick, M. A., Martin, J. K., Nagorney, D. M., Kvols, L. K., Rubin, J., & Kunselman, S. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-4-199402150-00008 · Cited by 292
Prognosis and Survival in Patients With Gastrointestinal Tract Carcinoid Tumors
Shebani, K. O., Souba, W. W., Finkelstein, D. M., Stark, P. C., Elgadi, K. M., Tanabe, K. K., & Ott, M. J. (1999) · Annals of Surgery · doi:10.1097/00000658-199906000-00008 · Cited by 266
Treatment of the carcinoid tumor and the malignant carcinoid syndrome.
Moertel, C. G. (1983) · Journal of Clinical Oncology · doi:10.1200/jco.1983.1.11.727 · Cited by 245
Carcinoid A Comprehensive Review
Schnirer, I. I., Yao, J. C., & Ajani, J. A. (2003) · Acta Oncologica · doi:10.1080/02841860310010547 · Cited by 192
Self-citationTranscatheter chemoembolization of progressive carcinoid liver metastasis.
Therasse, E., Breittmayer, F., Roche, A., De Baere, T., Indushekar, S., Ducreux, M., Lasser, P., Elias, D., & Rougier, P. (1993) · Radiology · doi:10.1148/radiology.189.2.7692465 · Cited by 172
Kress, O., Wagner, H., Wied, M., Klose, K.-J., Arnold, R., & Alfke, H. (2003) · Digestion · doi:10.1159/000074522 · Cited by 150
Prognostic variables in patients with gastrointestinal carcinoid tumours
McDermott, E. W. M., Gudurić, B., & Brennan, M. F. (1994) · British journal of surgery · doi:10.1002/bjs.1800810725 · Cited by 142
Pape, U., Böhmig, M., Berndt, U., Tiling, N., Wiedenmann, B., & Plöckinger, U. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1294.025 · Cited by 137
Drougas, J. G., Anthony, L. B., Blair, T. K., Lopez, R. R., Wright, J., Chapman, W. C., Webb, L., Mazer, M., Meranze, S. G., & Pinson, C. W. (1998) · The American Journal of Surgery · doi:10.1016/s0002-9610(98)00042-7 · Cited by 135
Survival of Patients with Disseminated Midgut Carcinoid Tumors after Aggressive Tumor Reduction
Wängberg, B., Westberg, G., Tylén, U., et al. (1996) · World Journal of Surgery · doi:10.1007/s002689900136 · Cited by 114
Öberg, K., Norheim, I., Lundqvist, G., & WIDE, L. E. (1987) · Acta Oncologica · doi:10.3109/02841868709113712 · Cited by 92
Hajarizadeh, H., Ivancev, K., Mueller, C. R., Fletcher, W. S., & Woltering, E. A. (1992) · The American Journal of Surgery · doi:10.1016/0002-9610(92)90392-5 · Cited by 85
Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested?
Välimäki, M. J., Järvinen, H., Salmela, P. I., Sane, T., Sjöblom, S. M., & Pelkonen, R. (1991) · Cancer · doi:10.1002/1097-0142(19910201)67:3<547::aid-cncr2820670302>3.0.co;2-j · Cited by 68
Hanssen, L. E., Schrumpf, E., Kolbenstvedt, A., Tausjø, J., & Dolva, L. Ø. (1989) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528909089215 · Cited by 62
Saltz, L. B., Kemeny, N. E., Schwartz, G. K., & Kelsen, D. P. (1994) · Cancer · doi:10.1002/1097-0142(19940801)74:3<958::aid-cncr2820740326>3.0.co;2-x · Cited by 61
p53 gene mutations and 17p allelic deletions in hepatocellular carcinoma from Japan
Nose, H., Imazeki, F., Ohto, M., & Omata, M. (1993) · Cancer · doi:10.1002/1097-0142(19930715)72:2
Cited by
Rinke, A., Müller, H.-H., Schade-Brittinger, C., Klose, K.-J., Barth, P., Wied, M., Mayer, C., Aminossadati, B., Pape, U.-F., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,508
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456
Gabriel, M., Decristoforo, C., Kendler, D., Dobrozemsky, G., Heute, D., Uprimny, C., Kovacs, P., Von Guggenberg, E., Bale, R., & Virgolini, I. J. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.035667 · Cited by 1,010
Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V, et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300831 · Cited by 952
Gastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine Tumors
Metz, D. C., & Jensen, R. T. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.047 · Cited by 816
Metadata
- Authors
- Gupta, S., Johnson, M. M., Murthy, R., Ahrar, K., Wallace, M. J., Madoff, D. C., McRae, S. E., Hicks, M. E., Rao, S., Vauthey, J., Ajani, J. A., & Yao, J. C.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2005-10-03
- Volume
- 104
- Issue
- 8
- Pages
- 1590-1602
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1532334298
- Cited by
- 433
- References
- 19
- FWCI
- 17.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.